Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.07
+0.29005.02%
Post-market: 6.170.1000+1.65%19:30 EDT
Volume:5.74M
Turnover:34.88M
Market Cap:2.13B
PE:-13.84
High:6.16
Open:5.96
Low:5.92
Close:5.78
52wk High:9.75
52wk Low:2.99
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.89
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:8.40
PE(LYR):-10.12

Loading ...

Nuvation Bio participates in Bank of America Securities Healthcare Conference fireside chat

Reuters
·
May 06

Stock Track | Nuvation Bio Soars 5.33% Intraday on Positive Analyst Coverage and Maintained Price Targets

Stock Track
·
May 05

Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Evolus (EOLS) and Nuvation Bio (NUVB)

TIPRANKS
·
May 05

Nuvation Bio Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
May 05

Nuvation Bio publishes corporate presentation on IBTROZI ROS1 lung cancer drug```

Reuters
·
May 05

Nuvation Bio Q1 net income turns positive on IBTROZI sales

Reuters
·
May 05

Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.

Benzinga Earnings
·
May 05

BRIEF-Nuvation Bio Q1 EPS USD 0.01

Reuters
·
May 05

Nuvation Bio Q1 Pretax Profit USD 5.397 Million

THOMSON REUTERS
·
May 05

Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 05

BRIEF-Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option

Reuters
·
Apr 27

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

THOMSON REUTERS
·
Apr 27

Earning Preview: Nuvation Bio, Inc. Q1 revenue is expected to increase by 14,240.76%, and institutional views are bullish

Earnings Agent
·
Apr 27

Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI

TIPRANKS
·
Apr 22

Nuvation Bio publishes corporate presentation on IBTROZI launch, oncology pipeline updates

Reuters
·
Apr 22

Nuvation Bio says pooled TRUST data show 49.7-month IBTROZI response duration

Reuters
·
Apr 22

Nuvation Bio Chief Regulatory Officer Kerry Wentworth sells 36,750 shares for $184,279

Reuters
·
Apr 22

Nuvation Bio CMO Liu Dongfang disposes 50,000 common shares for $251,000

Reuters
·
Apr 22

Nuvation Bio publishes 2025 annual report to stockholders

Reuters
·
Apr 21